Abstract 41P
Background
Prostate cancer is the second leading cause of cancer death among men in the United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced disease stage in which patients ultimately fail androgen-deprivation therapies and exhibit a poor survival rate. Recently, prostate-specific membrane antigen (PSMA) has been validated as a mCRPC tumor antigen with its over-expression in tumors and low expression in healthy tissues. Using an expanded genetic code to create Engineered Precision Biologics, Ambrx has developed ARX517, a PSMA-targeted antibody drug conjugate (ADC), which is composed of a humanized anti-PSMA antibody site-specifically conjugated to a tubulin inhibitor drug-linker at a drug-to-antibody ratio of 2. After binding to PSMA, ARX517 is internalized and catabolized, leading to cytotoxic payload delivery and cellular apoptosis. To minimize premature payload release and maximize delivery to tumor microenvironments, ARX517 employs a non-cleavable PEG linker and stable oxime conjugation chemistry, enhancing systemic stability.
Methods
ARX517 was evaluated in multiple pre-clinical pharmacology and toxicology models using standard methodology.
Results
In vitro studies demonstrate that ARX517 selectively induces cytotoxicity of PSMA-expressing tumor lines. ARX517 exhibited a long terminal half-life and high serum exposure in mice, and dose-dependent anti-tumor activity in both enzalutamide-sensitive and -resistant CDX and PDX prostate cancer models. Repeat dose toxicokinetic studies in non-human primates demonstrated ARX517 was tolerated at exposures well above therapeutic exposures in mouse pharmacology studies, indicating a wide therapeutic index.
Conclusions
In summary, ARX517 inhibited tumor growth in diverse mCRPC models, demonstrated a tolerable safety profile in monkeys, and had a wide therapeutic index based on preclinical exposure data. Based on strong preclinical data and recent clinical validation of PSMA targeting, ARX517 is being evaluated in a phase 1/2 clinical trial (NCT04662580).
Clinical trial identification
Editorial acknowledgement
Mark English, PhD, of Cancer Communications and Consultancy Ltd, Cheshire, UK, provided editorial assistance (funded by Ambrx).
Legal entity responsible for the study
Ambrx.
Funding
Ambrx.
Disclosure
S. Zhang, D. Mills, J.Y. Kim, N. Knudsen, J. Nelson, Y. Buechler, L. Skidmore: Financial Interests, Personal, Full or part-time Employment: Ambrx.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09